Name (Synonyms) | Correlation | |
---|---|---|
drug847 | Data record Wiki | 0.71 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to determine if administration of angiotensin-(1-7) / TXA127 prevents acute kidney injury and deterioration into multi-organ failure in patients with moderate to severe COVID-19
Description: Defined as an increase of serum creatinine by more than 0.3 mg/dL or 50% above baseline (at enrollment)
Measure: Incidence of acute kidney injury Time: Day 1 to Day 7Description: Requiring intubation and ventilatory support
Measure: Incidence of respiratory failure Time: Day 1 to Day 7Description: death
Measure: Mortality Time: Day 1 to Day 7Description: Requiring dialysis (either continuous or intermittent)
Measure: Renal failure Time: Day 1 to Day 7Description: requiring vasopressors
Measure: Vasoplegic shock Time: Day 1 to Day 7Description: measured via blood work
Measure: Inflammatory markers, specifically IL-6 levels Time: Day 1 to Day 7Description: defined as a reduction in oxygen requirements from start of experimental drug
Measure: Reduction in supplemental oxygen requirements Time: Day 1 to Day 7